Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.

Cox AR, Lam CJ, Rankin MM, Rios JS, Chavez J, Bonnyman CW, King KB, Wells RA, Anthony D, Tu JX, Kim JJ, Li C, Kushner JA.

Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.

2.

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC.

Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.

3.

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.

Ueberberg S, Jütte H, Uhl W, Schmidt W, Nauck M, Montanya E, Tannapfel A, Meier J.

Diabetes Obes Metab. 2016 Dec;18(12):1253-1262. doi: 10.1111/dom.12766. Epub 2016 Sep 26. Erratum in: Diabetes Obes Metab. 2017 Feb;19(2):306.

PMID:
27545110
4.

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.

Aston-Mourney K, Subramanian SL, Zraika S, Samarasekera T, Meier DT, Goldstein LC, Hull RL.

Am J Physiol Endocrinol Metab. 2013 Aug 15;305(4):E475-84. doi: 10.1152/ajpendo.00025.2013. Epub 2013 Jun 4.

5.

Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.

Mondragon A, Davidsson D, Kyriakoudi S, Bertling A, Gomes-Faria R, Cohen P, Rothery S, Chabosseau P, Rutter GA, da Silva Xavier G.

PLoS One. 2014 Aug 13;9(8):e104873. doi: 10.1371/journal.pone.0104873. eCollection 2014.

6.

beta-cell failure in diabetes and preservation by clinical treatment.

Wajchenberg BL.

Endocr Rev. 2007 Apr;28(2):187-218. Epub 2007 Mar 12. Review.

PMID:
17353295
7.

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Siddiqui NI.

Mymensingh Med J. 2009 Jan;18(1):113-24. Review.

PMID:
19182763
8.

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.

Diabetes. 2006 Jun;55(6):1695-704.

9.

Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.

Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17.

PMID:
19766644
10.

Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.

Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.

Diabetes Obes Metab. 2017 May;19(5):705-712. doi: 10.1111/dom.12879. Epub 2017 Mar 10.

PMID:
28094469
11.

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.

Harja E, Lord J, Skyler JS.

Diabetes Technol Ther. 2013 Aug;15(8):609-18. doi: 10.1089/dia.2013.0177. Epub 2013 Aug 8.

PMID:
23927624
12.

Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?

Lamont BJ, Andrikopoulos S.

J Endocrinol. 2014 Mar 7;221(1):T43-61. doi: 10.1530/JOE-13-0577. Print 2014 Apr. Review.

PMID:
24424288
13.

High fat diet and GLP-1 drugs induce pancreatic injury in mice.

Rouse R, Xu L, Stewart S, Zhang J.

Toxicol Appl Pharmacol. 2014 Apr 15;276(2):104-14. doi: 10.1016/j.taap.2014.01.021. Epub 2014 Feb 15.

PMID:
24534256
14.

Incretin hormones and beta-cell mass expansion: what we know and what is missing?

Tortosa F, Dotta F.

Arch Physiol Biochem. 2013 Oct;119(4):161-9. doi: 10.3109/13813455.2013.795175. Epub 2013 May 23. Review.

PMID:
23697580
15.

Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.

García Díaz E, Guagnozzi D, Gutiérrez V, Mendoza C, Maza C, Larrañaga Y, Perdomo D, Godoy T, Taleb G.

Endocrinol Nutr. 2016 May;63(5):194-201. doi: 10.1016/j.endonu.2016.01.006. Epub 2016 Mar 11. English, Spanish.

PMID:
26976710
16.

The effects of glucagon-like peptide-1 on the beta cell.

Vilsbøll T.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:11-8. doi: 10.1111/j.1463-1326.2009.01073.x. Review.

PMID:
19878257
17.

Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.

Kang ZF, Deng Y, Zhou Y, Fan RR, Chan JC, Laybutt DR, Luzuriaga J, Xu G.

Diabetologia. 2013 Feb;56(2):423-33. doi: 10.1007/s00125-012-2776-x. Epub 2012 Nov 28.

18.

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.

Bonner-Weir S, In't Veld PA, Weir GC.

Diabetes Obes Metab. 2014 Jul;16(7):661-6. doi: 10.1111/dom.12257. Epub 2014 Jan 29.

19.

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.

Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P; DURATION-NEO-2 study investigators.

Diabetes Obes Metab. 2017 Jul;19(7):979-988. doi: 10.1111/dom.12908. Epub 2017 Mar 17. Erratum in: Diabetes Obes Metab. 2017 Sep;19(9):1332.

20.

Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.

Moonschi FH, Hughes CB, Mussman GM, Fowlkes JL, Richards CI, Popescu I.

Acta Diabetol. 2018 May;55(5):405-418. doi: 10.1007/s00592-017-1086-7. Epub 2017 Dec 20. Review.

PMID:
29264724

Supplemental Content

Support Center